307 related articles for article (PubMed ID: 30187345)
1. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
Zhang J; Shao Y; Liu Y; Tao J
Cardiovasc Drugs Ther; 2018 Dec; 32(6):581-589. PubMed ID: 30187345
[TBL] [Abstract][Full Text] [Related]
2. Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial.
Park JB; Jung JH; Yoon YE; Kim HL; Lee SP; Kim HK; Kim YJ; Cho GY; Sohn DW
Trials; 2017 Oct; 18(1):501. PubMed ID: 29078817
[TBL] [Abstract][Full Text] [Related]
3. Effect of pitavastatin and atorvastatin on regression of atherosclerosis assessed using intravascular ultrasound: a meta-analysis.
Liu H; Zhang M; Li D; Tian J; Wang X; Pan J; Liu D; Li X; An F
Coron Artery Dis; 2018 Sep; 29(6):459-468. PubMed ID: 29738341
[TBL] [Abstract][Full Text] [Related]
4. Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study.
Tarim BA; Fici F; Tengiz I; Avunduk S; Ozcan Y; Faikoglu G; Ari E; Robles NR; Grassi G
Yonsei Med J; 2023 Mar; 64(3):175-180. PubMed ID: 36825343
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin: clinical effects from the LIVES Study.
Teramoto T
Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
[TBL] [Abstract][Full Text] [Related]
6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
7. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes.
Vallejo-Vaz AJ; Kondapally Seshasai SR; Kurogi K; Michishita I; Nozue T; Sugiyama S; Tsimikas S; Yoshida H; Ray KK
Atherosclerosis; 2015 Aug; 241(2):409-18. PubMed ID: 26074315
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
9. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Liu PY; Lin LY; Lin HJ; Hsia CH; Hung YR; Yeh HI; Wu TC; Chen JY; Chien KL; Chen JW
PLoS One; 2013; 8(10):e76298. PubMed ID: 24098467
[TBL] [Abstract][Full Text] [Related]
10. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin in cardiometabolic disease: therapeutic profile.
Masana L
Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
Taguchi I; Iimuro S; Iwata H; Takashima H; Abe M; Amiya E; Ogawa T; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Miyauchi K; Yamazaki T; Ito H; Otsuji Y; Kimura K; Takahashi J; Hirayama A; Yokoi H; Kitagawa K; Urabe T; Okada Y; Terayama Y; Toyoda K; Nagao T; Matsumoto M; Ohashi Y; Kaneko T; Fujita R; Ohtsu H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Inoue T; Matsuzaki M; Nagai R
Circulation; 2018 May; 137(19):1997-2009. PubMed ID: 29735587
[TBL] [Abstract][Full Text] [Related]
13. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Gumprecht J; Gosho M; Budinski D; Hounslow N
Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
[TBL] [Abstract][Full Text] [Related]
14. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up.
Jeong HS; Hong SJ; Son S; An H; Kook H; Joo HJ; Park JH; Yu CW; Lim DS
Cardiovasc Diabetol; 2019 Nov; 18(1):162. PubMed ID: 31752850
[TBL] [Abstract][Full Text] [Related]
15. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
16. Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.
Nakagomi A; Shibui T; Kohashi K; Kosugi M; Kusama Y; Atarashi H; Shimizu W
J Atheroscler Thromb; 2015; 22(11):1158-71. PubMed ID: 26084792
[TBL] [Abstract][Full Text] [Related]
17. Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study.
Wan EYF; Fung CSC; Yu EYT; Chin WY; Fong DYT; Chan AKC; Lam CLK
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862945
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
[TBL] [Abstract][Full Text] [Related]
20. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals.
Saito Y
Vasc Health Risk Manag; 2009; 5():921-36. PubMed ID: 19997573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
